Bristol Myers Squibb: Value Emerges From Distress
Bristol Myers Squibb offers a compelling value entry for long-term income investors, despite looming patent cliffs and execution risks. BMY's growth portfolio is positioned to offset revenue losses from Eliquis and Opdivo expirations, supporting a moderate long-term revenue CAGR. Current valuations reflect excessive pessimism, trading at a 25% discount to BMY's five-year average, with downside risk already priced in.
Bristol Myers buys Orbital Therapeutics for $1.5 billion
Drugmaker Bristol Myers Squibb said on Friday it will acquire privately held cell therapy developer Orbital Therapeutics for $1.5 billion in cash.
Bristol-Myers Squibb: Your Chance To Buy A Bargain 6% Yield
Bristol-Myers Squibb offers a compelling value at current lows, trading at under 7x earnings and yielding an attractive 6% dividend. BMY's resilient business model, strong cash flow, and growth from new drugs like Breyanzi offset legacy drug declines. Political risks are manageable for BMY as a US-based company, with potential policy changes likely to have limited impact on its bottom line.
Can BMYs Neuroscience Portfolio Help to Diversify Its Business?
Bristol Myers gains FDA Fast Track status for its Alzheimer's antibody BMS-986446 as Cobenfy drives early sales and pipeline momentum.
Why Bristol Myers Squibb (BMY) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market: Important Facts to Note
In the closing of the recent trading day, Bristol Myers Squibb (BMY) stood at $44.66, denoting a -1.06% move from the preceding trading day.
Billionaires Are Piling Into United Health Group and These 2 Stocks
UnitedHealth Group (NYSE:UNH ), Bristol-Myers Squibb (NYSE:BMY) and Fiserv (NYSE:FI) have been getting plenty of attention from big name investors.
Bristol Myers, Takeda to pool data for AI-based drug discovery
Bristol Myers Squibb , Takeda Pharmaceuticals and Astex Pharmaceuticals are coming together to share proprietary data for training an artificial intelligence model to assist drug discovery and development.
Bristol Myers Squibb (BMY) Beats Stock Market Upswing: What Investors Need to Know
Bristol Myers Squibb (BMY) reached $45.1 at the closing of the latest trading day, reflecting a +2.15% change compared to its last close.
Bristol Myers plans to launch schizophrenia drug in UK at list price equal to the US
Bristol Myers Squibb said on Monday that it plans to launch its schizophrenia treatment Cobenfy in the UK in 2026 at a price that is equal to its US list price.
Bristol Myers Squibb: Buy This Deep Bargain Before The Market Wakes To Income
Bristol Myers Squibb is a deep value opportunity, trading at a forward PE of 7x and offering a 5.5% dividend yield. BMY's next-gen portfolio drives double-digit growth, with blockbuster drugs like Reblozyl and Camzyos offsetting legacy declines. Strategic partnerships, a robust pipeline, and expanding opportunities in oncology and Alzheimer's position BMY for long-term relevance.
Bristol Myers to sell 60% stake in China joint venture
U.S. drugmaker Bristol Myers Squibb said on Tuesday it has signed an agreement to sell its 60% ownership stake in a pharmaceutical joint venture in China.
